A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma

A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma

In 2021, pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer deaths in the United States. This is largely due to a lack of symptoms and limited treatment options, which extend survival by only a few weeks. There is thus an urgent need to develop new therapies effective against...

Full description

Bibliographic Details
Main Authors: Clayton S. Lewis, Aniruddha Karve, Kateryna Matiash, Timothy Stone, Jingxing Li, Jordon K. Wang, Henri H. Versteeg, Bruce J. Aronow, Syed A. Ahmad, Pankaj B. Desai, Vladimir Y. Bogdanov
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
pancreatic ductal adenocarcinoma
tissue factor
alternative splicing
monoclonal antibodies
orthotopic tumor model
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.691685/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.691685/full

Similar Items